These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia. Convit A; Volavka J; Czobor P; de Asis J; Evangelista C Am J Psychiatry; 1994 Jan; 151(1):49-56. PubMed ID: 8267134 [TBL] [Abstract][Full Text] [Related]
29. RBC and plasma levels of haloperidol and clinical response in schizophrenia. Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432 [TBL] [Abstract][Full Text] [Related]
30. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia. Stevens A; Mahal A; Gaertner HJ Pharmacopsychiatry; 1992 Sep; 25(5):218-23. PubMed ID: 1409866 [TBL] [Abstract][Full Text] [Related]
31. Higher than usual dosage of haloperidol: a pilot study in chronic schizophrenics. Pacquay M; Brasseur F Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):46-9. PubMed ID: 798190 [TBL] [Abstract][Full Text] [Related]
32. Hostility of drug-free patients with schizophrenia and n-3 polyunsaturated fatty acid levels in red blood cells. Watari M; Hamazaki K; Hirata T; Hamazaki T; Okubo Y Psychiatry Res; 2010 May; 177(1-2):22-6. PubMed ID: 20227767 [TBL] [Abstract][Full Text] [Related]
33. Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Magliozzi JR; Hollister LE; Arnold KV; Earle GM Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835 [TBL] [Abstract][Full Text] [Related]
34. Correlates of rapid neuroleptic response in male patients with schizophrenia. Petrie EC; Faustman WO; Moses JA; Lombrozo L; Csernansky JG Psychiatry Res; 1990 Aug; 33(2):171-7. PubMed ID: 2243894 [TBL] [Abstract][Full Text] [Related]
35. Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics. Selman FB; McClure RF; Helwig H Curr Ther Res Clin Exp; 1976 Jun; 19(6):645-52. PubMed ID: 819222 [No Abstract] [Full Text] [Related]
36. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. Gerlach J; Behnke K; Heltberg J; Munk-Anderson E; Nielsen H Br J Psychiatry; 1985 Sep; 147():283-8. PubMed ID: 3904885 [TBL] [Abstract][Full Text] [Related]
38. Haloperidol and reduced haloperidol concentrations and psychiatric ratings in schizophrenic patients treated with ascorbic acid. Straw GM; Bigelow LB; Kirch DG J Clin Psychopharmacol; 1989 Apr; 9(2):130-2. PubMed ID: 2566628 [TBL] [Abstract][Full Text] [Related]
39. Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid. Aymard N; Viala A; Stein I; Caroli F Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1119-35. PubMed ID: 8787036 [TBL] [Abstract][Full Text] [Related]
40. A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Fux M; Belmaker RH Isr J Psychiatry Relat Sci; 1991; 28(1):37-40. PubMed ID: 1830565 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]